Anna Kufner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anna Kufner has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
Matthias Endres
Klinik Für Neurologie Mit Experimenteller Neurologie, Charité –Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany
13 shared publicationsUchralt Temuulen
Klinik Für Neurologie Mit Experimenteller Neurologie, Charité –Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany
10 shared publications- Ulrike Grittner
Institute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Berlin, Germany
8 shared publications - Ahmed A. Khalil
Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Klinik für Neurologie mit Experimenteller Neurologie Germany (A.S.R., U.T., A.A.K., K.V., M.B., T.R., A.H.N., P.S.S., T.G.L., C.O., M.E., A.K.).
7 shared publications - Jochen B. Fiebach
Centre for Stroke Research Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany
7 shared publications - Matthias Endres
Center for Stroke Research Berlin (CSB), Charité-Universitätsmedizin Berlin, Berlin, Germany
7 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (9) , 524
Neuroanatomical correlates of stroke-related dizziness and vertigo: secondary analysis from the INSPiRE-TMS trial
Dizziness and vertigo are common and debilitating neurological symptoms among patients visiting the emergency department (ED). Possibly because the symptoms are not captured by standard stroke severity tools such as the NIHSS (National Institutes of Health Stroke Scale), their network-level neuroanatomical correlates—particularly potential supratentorial contributions—remain incompletely characterized. Therefore, we aim to investigate the neuroanatomical substrates of post-stroke dizziness and vertigo. This retrospective analysis included patients with acute ischemic stroke from the randomized controlled INSPiRE-TMS trial. Each patient underwent MRI within seven days of symptom onset, and stroke severity was assessed using the NIHSS at hospital admission. Patients were assessed for broadly defined new-onset dizziness/vertigo associated with the acute cerebrovascular event. Lesion symptom mapping (LSM) and lesion network mapping (LNM) were used to investigate associations between lesion location, functional connectivity, and dizziness/vertigo. Among 484 patients, 32% ( n = 157) reported dizziness at stroke onset. Notably, dizziness was reported in 22% (77/347) of patients with supratentorial lesions, compared with 58% (80/137) of those with infratentorial lesions. Patients with dizziness were more often female (36.9% vs. 27.8%, p = 0.042) and more frequently had hemianopia (35.1% vs. 15.6%, p < 0.0001). LSM identified cerebellar clusters (left lobules VI, Crus I–II, VIIb, VIIIa, and bilateral lobule IX with the vermis) associated with visuospatial and multisensory processing. LNM revealed a dizziness network involving left-dominant cerebellar regions, the brainstem, and higher-order visual areas, including the occipital pole, lingual gyrus, and fusiform gyrus. This network remained robust across subgroups stratified by lesion location (supra- vs. infratentorial) and after adjusting for age, sex, lesion volume, and hemianopia. Exploratory subtype comparisons suggested that lesions associated with vertigo showed relatively stronger connectivity to midline cerebellar structures (vermis), whereas those associated with swaying dizziness involved broader cerebellar hemispheres, although the overall network pattern was spatially similar and centered on the cerebellum. In conclusion, broadly defined post-stroke dizziness/vertigo symptoms were associated with a consistent lesion network involving cerebellar and occipital regions, suggesting involvement of distributed visual, vestibular, and multisensory brain systems. These findings may help guide future studies aimed at improving diagnostic evaluation and treatment of affected patients. ClinicalTrials.gov (NCT01586702; https://clinicaltrials.gov/ct2/show/NCT01586702 ); first registry in April 2012; first patient recruitment: September 2011.
- 12 August 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (9) , 524
Open AccessNeuroanatomical correlates of stroke-related dizziness and vertigo: secondary analysis from the INSPiRE-TMS trial
Dizziness and vertigo are common and debilitating neurological symptoms among patients visiting the emergency department (ED). Possibly because the symptoms are not captured by standard stroke severity tools such as the NIHSS (National Institutes of Health Stroke Scale), their network-level neuroanatomical correlates—particularly potential supratentorial contributions—remain incompletely characterized. Therefore, we aim to investigate the neuroanatomical substrates of post-stroke dizziness and vertigo. This retrospective analysis included patients with acute ischemic stroke from the randomized controlled INSPiRE-TMS trial. Each patient underwent MRI within seven days of symptom onset, and stroke severity was assessed using the NIHSS at hospital admission. Patients were assessed for broadly defined new-onset dizziness/vertigo associated with the acute cerebrovascular event. Lesion symptom mapping (LSM) and lesion network mapping (LNM) were used to investigate associations between lesion location, functional connectivity, and dizziness/vertigo. Among 484 patients, 32% ( n = 157) reported dizziness at stroke onset. Notably, dizziness was reported in 22% (77/347) of patients with supratentorial lesions, compared with 58% (80/137) of those with infratentorial lesions. Patients with dizziness were more often female (36.9% vs. 27.8%, p = 0.042) and more frequently had hemianopia (35.1% vs. 15.6%, p < 0.0001). LSM identified cerebellar clusters (left lobules VI, Crus I–II, VIIb, VIIIa, and bilateral lobule IX with the vermis) associated with visuospatial and multisensory processing. LNM revealed a dizziness network involving left-dominant cerebellar regions, the brainstem, and higher-order visual areas, including the occipital pole, lingual gyrus, and fusiform gyrus. This network remained robust across subgroups stratified by lesion location (supra- vs. infratentorial) and after adjusting for age, sex, lesion volume, and hemianopia. Exploratory subtype comparisons suggested that lesions associated with vertigo showed relatively stronger connectivity to midline cerebellar structures (vermis), whereas those associated with swaying dizziness involved broader cerebellar hemispheres, although the overall network pattern was spatially similar and centered on the cerebellum. In conclusion, broadly defined post-stroke dizziness/vertigo symptoms were associated with a consistent lesion network involving cerebellar and occipital regions, suggesting involvement of distributed visual, vestibular, and multisensory brain systems. These findings may help guide future studies aimed at improving diagnostic evaluation and treatment of affected patients. ClinicalTrials.gov (NCT01586702; https://clinicaltrials.gov/ct2/show/NCT01586702 ); first registry in April 2012; first patient recruitment: September 2011.
- Open Access
- 24 June 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (6) , e70678
Who Falls After a Stroke? Evidence From a Prospective Stroke Cohort
Background: Falls affect over 30% of stroke survivors within the first year, yet lesion‐related mobility and gait impairments underlying fall risk remain poorly understood. This study aimed to identify lesion‐derived functional networks associated with impaired mobility, gait, and fall risk in subacute stroke, and to determine whether disruption to these networks is associated with falls during the six‐month follow‐up. Methods: We analyzed data from 94 patients with disabling subacute ischemic stroke from the prospective Baptize cohort, an imaging sub‐cohort of the multicenter PHYS‐STROKE trial. Principal component (PC) analysis reduced seven mobility‐related and four gait‐related baseline variables into two composites: PC1‐Mobility and PC1‐Gait, explaining 56% and 82% of variance, respectively. PC1‐Mobility indexed global disability, whereas PC1‐Gait reflected spatiotemporal walking capacity. Lesion network mapping (LNM) identified functional networks associated with each domain. Patient‐reported falls up to six months post‐enrollment were the primary endpoint. Results: LNM revealed that the mobility‐related network predominantly involved cortical regions, whereas the gait‐related network was linked to subcortical and infratentorial connectivity. In binary multivariable logistic regression, network similarity scores were not associated with falls; only older age was significant (adjusted OR 1.08, 95% CI 1.02–1.16, p = 0.01). LNM of fall occurrence identified a cortical network with significant spatial overlap with the mobility‐related network ( p < 0.001). Conclusion: This exploratory, hypothesis‐generating study identified distinct functional networks for post‐stroke mobility and gait impairment. Falls may be more closely linked to disruptions in cortical networks supporting voluntary motor control and whole‐body coordination than to subcortical gait‐modulating structures, potentially informing fall risk stratification and targeted prevention. Trial Registration: ClinicalTrials.gov identifiers: BAPTISe: NCT01954797, PHYS‐STROKE: NCT01363856
- 24 June 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (6) , e70678
Open AccessWho Falls After a Stroke? Evidence From a Prospective Stroke Cohort
Background: Falls affect over 30% of stroke survivors within the first year, yet lesion‐related mobility and gait impairments underlying fall risk remain poorly understood. This study aimed to identify lesion‐derived functional networks associated with impaired mobility, gait, and fall risk in subacute stroke, and to determine whether disruption to these networks is associated with falls during the six‐month follow‐up. Methods: We analyzed data from 94 patients with disabling subacute ischemic stroke from the prospective Baptize cohort, an imaging sub‐cohort of the multicenter PHYS‐STROKE trial. Principal component (PC) analysis reduced seven mobility‐related and four gait‐related baseline variables into two composites: PC1‐Mobility and PC1‐Gait, explaining 56% and 82% of variance, respectively. PC1‐Mobility indexed global disability, whereas PC1‐Gait reflected spatiotemporal walking capacity. Lesion network mapping (LNM) identified functional networks associated with each domain. Patient‐reported falls up to six months post‐enrollment were the primary endpoint. Results: LNM revealed that the mobility‐related network predominantly involved cortical regions, whereas the gait‐related network was linked to subcortical and infratentorial connectivity. In binary multivariable logistic regression, network similarity scores were not associated with falls; only older age was significant (adjusted OR 1.08, 95% CI 1.02–1.16, p = 0.01). LNM of fall occurrence identified a cortical network with significant spatial overlap with the mobility‐related network ( p < 0.001). Conclusion: This exploratory, hypothesis‐generating study identified distinct functional networks for post‐stroke mobility and gait impairment. Falls may be more closely linked to disruptions in cortical networks supporting voluntary motor control and whole‐body coordination than to subcortical gait‐modulating structures, potentially informing fall risk stratification and targeted prevention. Trial Registration: ClinicalTrials.gov identifiers: BAPTISe: NCT01954797, PHYS‐STROKE: NCT01363856
- 1 May 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (5) , 1283-1297
CD177 Expression on Neutrophils Predicts Ischemic Stroke Outcome in Humans
BACKGROUND: Neutrophil granulocytes actively contribute to tissue damage after ischemic stroke. The membrane protein CD (cluster of differentiation)177 is detectable on variable neutrophil numbers in most individuals (CD177 wild-type [CD177 WT ] genotype), whereas ≈5% of the general population completely lack CD177 (CD177-deficient [CD177 null ] genotype). Despite its known relevance in vasculitis, the role of ischemic stroke remains unknown. METHODS: In 2 prospective cohorts of patients with first-ever ischemic stroke (PROSCIS-B [Prospective Cohort With Incident Stroke Berlin], NOFF-S [Neutrophils: Origin, Fate & Function Stroke]), we assessed the effect of CD177 null and CD177 WT status on stroke severity and outcome (National Institutes of Health Stroke Scale and modified Rankin Scale) over 1 year or 3 months poststroke, respectively. By flow cytometry, we stratified CD177 expression level as CD177 neg , CD177 dim , and CD177 high . The predictive value of the CD177 state was evaluated by multivariable regression and discrimination analyses. RESULTS: In PROSCIS‐B (n=579; mean age, 68.1 years; 38.5% women) and NOFF-S (n=236, 68.4 years, 36.9% women), similar rates of patients were CD177 null (n=26 [4.5%] and n=10 [4.2%], respectively). Patients with CD177 null had a higher probability of unfavorable stroke outcome (modified Rankin Scale score 3–6) than patients with CD177 WT (n=8 of 21 [38.1%] versus 90 of 462 [19.5%] with follow-up, P =0.05, in PROSCIS-B; n=8 of 10 [80.0%] versus n=23 of 142 [16.2%] with follow-up, P P dim neutrophils at admission was negatively associated with stroke severity at admission, while that of CD177 high neutrophils predicted a favorable clinical outcome after 3 months. CD177 expression level significantly improved the prediction of stroke outcome in addition to clinical adjustment variables in area under the curve, net reclassification improvement, and integrated discrimination improvement analyses ( P =0.004, P =0.001, and P high ). CONCLUSIONS: CD177 expression at admission is an easy-to-measure biomarker for patient stratification. CD177 holds potential as a therapeutic target to modulate immune responses after stroke. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01363856. URL: https://drks.de/search/en/trial/Unique identifier: DRKS00030825.
- 1 May 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (5) , 1283-1297
CD177 Expression on Neutrophils Predicts Ischemic Stroke Outcome in Humans
BACKGROUND: Neutrophil granulocytes actively contribute to tissue damage after ischemic stroke. The membrane protein CD (cluster of differentiation)177 is detectable on variable neutrophil numbers in most individuals (CD177 wild-type [CD177 WT ] genotype), whereas ≈5% of the general population completely lack CD177 (CD177-deficient [CD177 null ] genotype). Despite its known relevance in vasculitis, the role of ischemic stroke remains unknown. METHODS: In 2 prospective cohorts of patients with first-ever ischemic stroke (PROSCIS-B [Prospective Cohort With Incident Stroke Berlin], NOFF-S [Neutrophils: Origin, Fate & Function Stroke]), we assessed the effect of CD177 null and CD177 WT status on stroke severity and outcome (National Institutes of Health Stroke Scale and modified Rankin Scale) over 1 year or 3 months poststroke, respectively. By flow cytometry, we stratified CD177 expression level as CD177 neg , CD177 dim , and CD177 high . The predictive value of the CD177 state was evaluated by multivariable regression and discrimination analyses. RESULTS: In PROSCIS‐B (n=579; mean age, 68.1 years; 38.5% women) and NOFF-S (n=236, 68.4 years, 36.9% women), similar rates of patients were CD177 null (n=26 [4.5%] and n=10 [4.2%], respectively). Patients with CD177 null had a higher probability of unfavorable stroke outcome (modified Rankin Scale score 3–6) than patients with CD177 WT (n=8 of 21 [38.1%] versus 90 of 462 [19.5%] with follow-up, P =0.05, in PROSCIS-B; n=8 of 10 [80.0%] versus n=23 of 142 [16.2%] with follow-up, P P dim neutrophils at admission was negatively associated with stroke severity at admission, while that of CD177 high neutrophils predicted a favorable clinical outcome after 3 months. CD177 expression level significantly improved the prediction of stroke outcome in addition to clinical adjustment variables in area under the curve, net reclassification improvement, and integrated discrimination improvement analyses ( P =0.004, P =0.001, and P high ). CONCLUSIONS: CD177 expression at admission is an easy-to-measure biomarker for patient stratification. CD177 holds potential as a therapeutic target to modulate immune responses after stroke. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01363856. URL: https://drks.de/search/en/trial/Unique identifier: DRKS00030825.
- Open Access
- 26 March 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (4) , e70578
Baseline Cerebral Small Vessel Disease Predicting Long‐Term Cognitive Decline in Transient Ischemic Attack Patients
Background: Cerebral small vessel disease (CSVD) is a common incidental MRI finding in patients with transient ischemic attack (TIA) and stroke and has been linked to cognitive decline. This study investigated the prevalence of CSVD imaging biomarkers in TIA patients and their association with cognitive performance over 3 years. Methods: We included 246 TIA patients from the INSPiRE‐TMS study ( ClinicalTrials.gov : NCT01586702). CSVD was assessed on baseline 3 T MRI using a composite score (0–4) including white matter hyperintensities (WMH), lacunes, cerebral microbleeds (CMBs), and enlarged perivascular spaces (PVS). Cognitive performance was evaluated using the Montreal Cognitive Assessment (MoCA) at baseline and annually for 3 years. Results: At least one CSVD imaging biomarker was present in 58.5% of patients. Lacunes (36.6%) were the most common, followed by PVS (28.1%), WMH (19.5%), and CMBs (17.9%). Higher CSVD‐score was independently associated with greater cognitive decline over 3 years ( β = −0.52, 95% CI −0.95– −0.08, p = 0.020), along with older age ( β = −0.08, 95% CI −0.13 to −0.03, p = 0.001). CMB burden was the strongest predictive component of the CSVD‐score ( β = 0.42, 95% CI −0.63 to −0.22, p < 0.001). CSVD‐score was particularly associated with decline in the memory domain (adjusted β of −0.18, 95% CI −0.32 to −0.04, p = 0.015). Conclusion: CSVD imaging markers are present in over half of TIA patients and are independently associated with cognitive decline up to 3 years, with the strongest effect on memory . Whether the presence of CMBs is the strongest predictive imaging biomarker of cognitive decline in TIA patients requires confirmation in further studies.
- 26 March 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (4) , e70578
Open AccessBaseline Cerebral Small Vessel Disease Predicting Long‐Term Cognitive Decline in Transient Ischemic Attack Patients
Background: Cerebral small vessel disease (CSVD) is a common incidental MRI finding in patients with transient ischemic attack (TIA) and stroke and has been linked to cognitive decline. This study investigated the prevalence of CSVD imaging biomarkers in TIA patients and their association with cognitive performance over 3 years. Methods: We included 246 TIA patients from the INSPiRE‐TMS study ( ClinicalTrials.gov : NCT01586702). CSVD was assessed on baseline 3 T MRI using a composite score (0–4) including white matter hyperintensities (WMH), lacunes, cerebral microbleeds (CMBs), and enlarged perivascular spaces (PVS). Cognitive performance was evaluated using the Montreal Cognitive Assessment (MoCA) at baseline and annually for 3 years. Results: At least one CSVD imaging biomarker was present in 58.5% of patients. Lacunes (36.6%) were the most common, followed by PVS (28.1%), WMH (19.5%), and CMBs (17.9%). Higher CSVD‐score was independently associated with greater cognitive decline over 3 years ( β = −0.52, 95% CI −0.95– −0.08, p = 0.020), along with older age ( β = −0.08, 95% CI −0.13 to −0.03, p = 0.001). CMB burden was the strongest predictive component of the CSVD‐score ( β = 0.42, 95% CI −0.63 to −0.22, p < 0.001). CSVD‐score was particularly associated with decline in the memory domain (adjusted β of −0.18, 95% CI −0.32 to −0.04, p = 0.015). Conclusion: CSVD imaging markers are present in over half of TIA patients and are independently associated with cognitive decline up to 3 years, with the strongest effect on memory . Whether the presence of CMBs is the strongest predictive imaging biomarker of cognitive decline in TIA patients requires confirmation in further studies.
- Open Access
Who Falls After Stroke? Evidence From a Prospective Stroke Cohort
Background: Falls are a frequent and serious complication after stroke, affecting more than 30% of survivors within the first year. While age and comorbidities are established risk factors for falls, stroke-specific contributors—particularly lesion-related impairments in mobility and gait—are less well understood and may inform targeted secondary prevention. Methods: We analyzed data from 94 patients with disabling subacute ischemic stroke enrolled in the prospective BAPTISe cohort, a predefined imaging and biomarker sub-cohort of the multicenter PHYS-STROKE trial. Detailed gait and mobility assessments were performed at baseline. Principal component (PC) analysis reduced seven mobility-related and four gait-related variables into two composite scores: PC1-Mobility and PC1-Gait, explaining 56% and 82% of variance, respectively. PC1-Mobility reflected global disability and functional mobility in daily life, whereas PC1-Gait captured spatiotemporal walking capacity and efficiency. Lesion network mapping (LNM) using a normative connectome identified functional networks associated with each domain. Patient-reported falls up to six months post-enrollment were the primary endpoint. Results: LNM of PC1-Mobility revealed a predominantly cortical network involving pre- and postcentral gyri, superior and middle frontal gyri, and sensorimotor integration areas. In contrast, PC1-Gait was associated with subcortical and infratentorial connectivity, including bilateral thalamus, brainstem, and cerebellum. In multivariable regression, network similarity scores were not independently associated with falls; only older age was significant (adjusted OR1.08, 95%CI1.02?1.15, p=0.013). LNM of fall occurrence showed a cortical network with significant spatial overlap with the PC1-Mobility network(p<0.001). Conclusion: This exploratory, hypothesis-generating study identified distinct lesion-derived functional networks associated with post-stroke mobility and gait impairment. Our findings suggest that falls may be more closely linked to disruptions in cortical networks involved in voluntary motor control and whole-body coordination, rather than subcortical structures primarily modulating gait. These results provide a foundation for future research aimed at improving fall risk stratification and targeted prevention strategies in stroke survivors.
Open AccessWho Falls After Stroke? Evidence From a Prospective Stroke Cohort
Background: Falls are a frequent and serious complication after stroke, affecting more than 30% of survivors within the first year. While age and comorbidities are established risk factors for falls, stroke-specific contributors—particularly lesion-related impairments in mobility and gait—are less well understood and may inform targeted secondary prevention. Methods: We analyzed data from 94 patients with disabling subacute ischemic stroke enrolled in the prospective BAPTISe cohort, a predefined imaging and biomarker sub-cohort of the multicenter PHYS-STROKE trial. Detailed gait and mobility assessments were performed at baseline. Principal component (PC) analysis reduced seven mobility-related and four gait-related variables into two composite scores: PC1-Mobility and PC1-Gait, explaining 56% and 82% of variance, respectively. PC1-Mobility reflected global disability and functional mobility in daily life, whereas PC1-Gait captured spatiotemporal walking capacity and efficiency. Lesion network mapping (LNM) using a normative connectome identified functional networks associated with each domain. Patient-reported falls up to six months post-enrollment were the primary endpoint. Results: LNM of PC1-Mobility revealed a predominantly cortical network involving pre- and postcentral gyri, superior and middle frontal gyri, and sensorimotor integration areas. In contrast, PC1-Gait was associated with subcortical and infratentorial connectivity, including bilateral thalamus, brainstem, and cerebellum. In multivariable regression, network similarity scores were not independently associated with falls; only older age was significant (adjusted OR1.08, 95%CI1.02?1.15, p=0.013). LNM of fall occurrence showed a cortical network with significant spatial overlap with the PC1-Mobility network(p<0.001). Conclusion: This exploratory, hypothesis-generating study identified distinct lesion-derived functional networks associated with post-stroke mobility and gait impairment. Our findings suggest that falls may be more closely linked to disruptions in cortical networks involved in voluntary motor control and whole-body coordination, rather than subcortical structures primarily modulating gait. These results provide a foundation for future research aimed at improving fall risk stratification and targeted prevention strategies in stroke survivors.
- Open Access
- 30 October 2025
- Published by Elsevier in NeuroImage: Clinical
- Vol. 48, 103895
Lesion Network Mapping of Acute Neurological Deficits and Its Prognostic Value After Ischemic Stroke
- 30 October 2025
- Published by Elsevier in NeuroImage: Clinical
- Vol. 48, 103895
Open AccessLesion Network Mapping of Acute Neurological Deficits and Its Prognostic Value After Ischemic Stroke
- 1 September 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (9) , 2527-2539
Lesion-Network Mapping of Poststroke Depressive Symptoms: Evidence From Two Prospective Ischemic Stroke Cohorts
BACKGROUND: Poststroke depression affects up to one-third of stroke survivors, significantly impacting recovery and quality of life. However, its pathophysiology remains unclear. METHODS: We analyzed 2 independent, prospective ischemic stroke cohorts (PROSCIS-B [Prospective Cohort of Incident Stroke Berlin] and BAPTISe [Biomarkers and Perfusion-Training-Induced Changes After Stroke]; n=377) enrolled at the Charité Hospital, Germany, to identify brain regions and networks associated with depressive symptoms poststroke. Lesion-symptom mapping assessed associations between lesion location and depressive symptoms measured by the Center for Epidemiological Studies Depression Scale at 6 (BAPTISe) or 12 (PROSCIS-B) months poststroke. Lesion-network mapping evaluated lesion connectivity with brain networks. A mixed-effects model, including cohort as a random effect, assessed the relationship between network similarity (Pearson correlation) and Center for Epidemiological Studies Depression Scale scores. Dice coefficients (DC) quantified spatial overlap with canonical resting-state networks. RESULTS: Lesion-symptom mapping showed no significant associations between lesion location and depressive symptoms. In contrast, lesion-network mapping revealed that lesion connectivity to brain regions including the frontal pole, middle and inferior frontal gyri, inferior temporal gyrus, supramarginal gyrus, angular gyrus, frontal orbital cortex, and thalamus weakly correlated with Center for Epidemiological Studies Depression Scale scores (β, 11.4 [95%CI, 1.8–21.1]; P =0.02). These regions overlapped with the frontoparietal (DC=0.28), salience (DC=0.27), and default mode (DC=0.20) networks, as well as a published depression circuit (DC=0.43). However, these findings did not replicate across data sets. CONCLUSIONS: Lesion location alone was not associated with poststroke depression. However, connectivity-based analyses implicated disruption of large-scale brain networks in the development of depressive symptoms. The failure to validate this association across data sets underscores the need for further studies with more comparable patient populations—particularly in terms of stroke severity and harmonized assessment time-points—to confirm these findings and their clinical relevance. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01363856. URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01954797.
- 1 September 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (9) , 2527-2539
Lesion-Network Mapping of Poststroke Depressive Symptoms: Evidence From Two Prospective Ischemic Stroke Cohorts
BACKGROUND: Poststroke depression affects up to one-third of stroke survivors, significantly impacting recovery and quality of life. However, its pathophysiology remains unclear. METHODS: We analyzed 2 independent, prospective ischemic stroke cohorts (PROSCIS-B [Prospective Cohort of Incident Stroke Berlin] and BAPTISe [Biomarkers and Perfusion-Training-Induced Changes After Stroke]; n=377) enrolled at the Charité Hospital, Germany, to identify brain regions and networks associated with depressive symptoms poststroke. Lesion-symptom mapping assessed associations between lesion location and depressive symptoms measured by the Center for Epidemiological Studies Depression Scale at 6 (BAPTISe) or 12 (PROSCIS-B) months poststroke. Lesion-network mapping evaluated lesion connectivity with brain networks. A mixed-effects model, including cohort as a random effect, assessed the relationship between network similarity (Pearson correlation) and Center for Epidemiological Studies Depression Scale scores. Dice coefficients (DC) quantified spatial overlap with canonical resting-state networks. RESULTS: Lesion-symptom mapping showed no significant associations between lesion location and depressive symptoms. In contrast, lesion-network mapping revealed that lesion connectivity to brain regions including the frontal pole, middle and inferior frontal gyri, inferior temporal gyrus, supramarginal gyrus, angular gyrus, frontal orbital cortex, and thalamus weakly correlated with Center for Epidemiological Studies Depression Scale scores (β, 11.4 [95%CI, 1.8–21.1]; P =0.02). These regions overlapped with the frontoparietal (DC=0.28), salience (DC=0.27), and default mode (DC=0.20) networks, as well as a published depression circuit (DC=0.43). However, these findings did not replicate across data sets. CONCLUSIONS: Lesion location alone was not associated with poststroke depression. However, connectivity-based analyses implicated disruption of large-scale brain networks in the development of depressive symptoms. The failure to validate this association across data sets underscores the need for further studies with more comparable patient populations—particularly in terms of stroke severity and harmonized assessment time-points—to confirm these findings and their clinical relevance. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01363856. URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01954797.
- Open Access
Neuroimaging Correlates of Post-Stroke Pain After Ischemic Stroke: Secondary Analysis of the INSPiRE-TMS Trial
Background Post-stroke pain (PSP) affects nearly half of stroke survivors, severely compromising quality of life. The causes of PSP remain underexplored, although there is likely a complex interplay of lesion effects, psychological factors and mobility that play a role in the development of PSP. The aim of the study was to investigate clinical characteristics associated with PSP, as well as structural and functional correlates of PSP using lesion symptom (LSM) and network mapping (LNM). Methods We analyzed data from the INSPiRE-TMS cohort, encompassing 1,022 minor ischemic stroke patients. Pain severity and psychological factors (EQ5D-3L questionnaire) were assessed annually for up to 3 years. In a sub-group of 391 patients with available imaging data, LSM and LNM analyses were conducted to identify neural correlates of PSP. Results Overall, 47% of patients reported pain 1-year post-stroke. Multivariable regression analyses identified baseline anxiety as being associated with PSP assessed at 1-year post-stroke (OR 2.90, 95% CI 1.17–7.17, p=0.021). LSM did not identify any voxels associated with new severe pain. LNM identified a network involving anterior cingulate cortex, thalamus and insular cortex. Adjusting for anxiety highlighted distinct network contributions, suggesting interactive effects of psychological states on pain perception. Automated comparison to large metanalytical findings using Neurosynth associated the terms ‘pain’ and ‘nociception’ most strongly to the identified network. Conclusion PSP is closely associated with psychological factors such as anxiety. LNM of PSP revealed disruptions in a pain-related neural network consistent with prior pain research. These results warrant external validation and could guide future network-targeted neuromodulation therapies. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT01586702.
Open AccessNeuroimaging Correlates of Post-Stroke Pain After Ischemic Stroke: Secondary Analysis of the INSPiRE-TMS Trial
Background Post-stroke pain (PSP) affects nearly half of stroke survivors, severely compromising quality of life. The causes of PSP remain underexplored, although there is likely a complex interplay of lesion effects, psychological factors and mobility that play a role in the development of PSP. The aim of the study was to investigate clinical characteristics associated with PSP, as well as structural and functional correlates of PSP using lesion symptom (LSM) and network mapping (LNM). Methods We analyzed data from the INSPiRE-TMS cohort, encompassing 1,022 minor ischemic stroke patients. Pain severity and psychological factors (EQ5D-3L questionnaire) were assessed annually for up to 3 years. In a sub-group of 391 patients with available imaging data, LSM and LNM analyses were conducted to identify neural correlates of PSP. Results Overall, 47% of patients reported pain 1-year post-stroke. Multivariable regression analyses identified baseline anxiety as being associated with PSP assessed at 1-year post-stroke (OR 2.90, 95% CI 1.17–7.17, p=0.021). LSM did not identify any voxels associated with new severe pain. LNM identified a network involving anterior cingulate cortex, thalamus and insular cortex. Adjusting for anxiety highlighted distinct network contributions, suggesting interactive effects of psychological states on pain perception. Automated comparison to large metanalytical findings using Neurosynth associated the terms ‘pain’ and ‘nociception’ most strongly to the identified network. Conclusion PSP is closely associated with psychological factors such as anxiety. LNM of PSP revealed disruptions in a pain-related neural network consistent with prior pain research. These results warrant external validation and could guide future network-targeted neuromodulation therapies. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT01586702.
- Open Access
- 12 May 2025
- Published by Springer Nature in Neurological Research and Practice
- Vol. 7 (1) , 1-9
Neuropsychiatric changes following striatal stroke– results from the observational PostPsyDis study
Background: Ischemic stroke can lead to neuropsychiatric sequelae such as depression and post-traumatic stress disorder (PTSD), resulting in poorer functional outcomes. The POST-stroke PSYchological DIStress PostPsyDis; NCT01187342) study aimed to investigate whether ischemic lesions in the striatum increase the risk of depression and PTSD after stroke. Methods: This monocenter, observational, case-control study included 84 ischemic stroke patients with striatal (n = 54) and non-striatal ischemic brain lesions (n = 30). Primary study endpoints included symptoms of depression (assessed via the Geriatric Depression Scale; GDS-30) and PTSD (assessed via the Posttraumatic Symptom Scale; PTSS-10) 90 days post-stroke. A normative functional connectome was used to obtain a measure of striatal connectivity to the rest of the brain (“striatal network”). Network damage scores were used to estimate damage of each lesion to the striatal network. Results: Patients with striatal lesions had higher GDS-30 scores at 90 days post-stroke (median 5.6 vs. 3.0; Cohen’s d = 0.39; p = 0.057), indicating a small to moderate effect. However, no meaningful group differences were observed in the incidence of depression or PTSD. In multivariable regression analyses, striatal infarction had an adjusted beta coefficient (β) of 1.9 (95%CI 0.19–3.7; p = 0.076) for GDS-10 and 1.8 (95%CI -1.9–5.5; p = 0.25) for PTSS-10 scores after 90 days. Only female sex was independently associated with PTSD severity (adjusted β = 5.1, 95% CI 1.3–8.8; p = 0.008). Analyzing lesion connectivity to the striatal network did not change these findings. Conclusions: Taken together, the PostPsyDis study suggests a high rate of psychiatric morbidity in stroke patients. Moreover, the study suggests increased neuropsychiatric symptoms in patients with striatal lesions. There is a clear need for larger studies to investigate the role of the striatum in post-stroke neuropsychiatric disorders. Trial registration: ClinicalTrials.gov (NCT01187342) Registered 23 August 2009, https://clinicaltrials.gov/study/NCT01187342.
- 12 May 2025
- Published by Springer Nature in Neurological Research and Practice
- Vol. 7 (1) , 1-9
Open AccessNeuropsychiatric changes following striatal stroke– results from the observational PostPsyDis study
Background: Ischemic stroke can lead to neuropsychiatric sequelae such as depression and post-traumatic stress disorder (PTSD), resulting in poorer functional outcomes. The POST-stroke PSYchological DIStress PostPsyDis; NCT01187342) study aimed to investigate whether ischemic lesions in the striatum increase the risk of depression and PTSD after stroke. Methods: This monocenter, observational, case-control study included 84 ischemic stroke patients with striatal (n = 54) and non-striatal ischemic brain lesions (n = 30). Primary study endpoints included symptoms of depression (assessed via the Geriatric Depression Scale; GDS-30) and PTSD (assessed via the Posttraumatic Symptom Scale; PTSS-10) 90 days post-stroke. A normative functional connectome was used to obtain a measure of striatal connectivity to the rest of the brain (“striatal network”). Network damage scores were used to estimate damage of each lesion to the striatal network. Results: Patients with striatal lesions had higher GDS-30 scores at 90 days post-stroke (median 5.6 vs. 3.0; Cohen’s d = 0.39; p = 0.057), indicating a small to moderate effect. However, no meaningful group differences were observed in the incidence of depression or PTSD. In multivariable regression analyses, striatal infarction had an adjusted beta coefficient (β) of 1.9 (95%CI 0.19–3.7; p = 0.076) for GDS-10 and 1.8 (95%CI -1.9–5.5; p = 0.25) for PTSS-10 scores after 90 days. Only female sex was independently associated with PTSD severity (adjusted β = 5.1, 95% CI 1.3–8.8; p = 0.008). Analyzing lesion connectivity to the striatal network did not change these findings. Conclusions: Taken together, the PostPsyDis study suggests a high rate of psychiatric morbidity in stroke patients. Moreover, the study suggests increased neuropsychiatric symptoms in patients with striatal lesions. There is a clear need for larger studies to investigate the role of the striatum in post-stroke neuropsychiatric disorders. Trial registration: ClinicalTrials.gov (NCT01187342) Registered 23 August 2009, https://clinicaltrials.gov/study/NCT01187342.
- Open Access
Cerebral Small Vessel Disease and Cognitive Decline Following Transient Ischemic Attack: A Longitudinal Study
Background: Cerebral small vessel disease (CSVD) is a common incidental finding on cerebral MRI in patients with transient ischemic attack (TIA) and stroke and has been linked to increased cerebrovascular risk and cognitive decline. This study aimed to investigate the prevalence of CSVD imaging biomarkers in TIA patients and evaluate their association with cognitive function over three years following the ischemic event. Methods: A cohort of 246 TIA patients from the INSPiRE-TMS (ClinicalTrials.gov: NCT01586702 ) study were included. The CSVD-score – including white matter hyperintensities (WMH), lacunes, cerebral microbleeds (CMBs), and enlarged perivascular spaces (PVS) – was assessed on baseline MRI. Cognitive performance was assessed via the Montreal Cognitive Assessment (MoCA) at baseline and annual outpatient visits up to 3 years. Results: CSVD was present in 58.5% of TIA patients. The most prevalent imaging biomarker was lacunes (36.6%), followed by PVS (28.1%), WMH (19.5%) and CMBs (17.9%). Cumulative CSVD-score (range 0-4) was an independently associated with cognitive decline up to 3 years (β = -0.53, 95% CI -0.97 – -0.09, p = 0.018), alongside advanced age (β = -0.08, 95% CI -0.13 – -0.03, p=0.001). CMB burden was the strongest predictive component of the CSVD-score (β = 0.42, 95% CI -0.63 – -0.21, p < 0.001). Specifically, CSVD-score had a significant negative effect on the memory domain of cognitive function with an adjusted β of - 0.18 (95% CI -0.32 – -0.04, p = 0.014). Conclusion: Imaging biomarkers of CSVD are present in more than half of TIA patients and are an independent predictor of cognitive decline up to 3 years, with the strongest effect on the memory domain of cognitive function. Whether the presence of CMBs is the strongest predictive imaging biomarker of cognitive decline in TIA patients requires confirmation in further studies.
Open AccessCerebral Small Vessel Disease and Cognitive Decline Following Transient Ischemic Attack: A Longitudinal Study
Background: Cerebral small vessel disease (CSVD) is a common incidental finding on cerebral MRI in patients with transient ischemic attack (TIA) and stroke and has been linked to increased cerebrovascular risk and cognitive decline. This study aimed to investigate the prevalence of CSVD imaging biomarkers in TIA patients and evaluate their association with cognitive function over three years following the ischemic event. Methods: A cohort of 246 TIA patients from the INSPiRE-TMS (ClinicalTrials.gov: NCT01586702 ) study were included. The CSVD-score – including white matter hyperintensities (WMH), lacunes, cerebral microbleeds (CMBs), and enlarged perivascular spaces (PVS) – was assessed on baseline MRI. Cognitive performance was assessed via the Montreal Cognitive Assessment (MoCA) at baseline and annual outpatient visits up to 3 years. Results: CSVD was present in 58.5% of TIA patients. The most prevalent imaging biomarker was lacunes (36.6%), followed by PVS (28.1%), WMH (19.5%) and CMBs (17.9%). Cumulative CSVD-score (range 0-4) was an independently associated with cognitive decline up to 3 years (β = -0.53, 95% CI -0.97 – -0.09, p = 0.018), alongside advanced age (β = -0.08, 95% CI -0.13 – -0.03, p=0.001). CMB burden was the strongest predictive component of the CSVD-score (β = 0.42, 95% CI -0.63 – -0.21, p < 0.001). Specifically, CSVD-score had a significant negative effect on the memory domain of cognitive function with an adjusted β of - 0.18 (95% CI -0.32 – -0.04, p = 0.014). Conclusion: Imaging biomarkers of CSVD are present in more than half of TIA patients and are an independent predictor of cognitive decline up to 3 years, with the strongest effect on the memory domain of cognitive function. Whether the presence of CMBs is the strongest predictive imaging biomarker of cognitive decline in TIA patients requires confirmation in further studies.